Wilson's disease: modification by L-DOPA.
D000293:Adolescent; D002614:Chelating Agents / Q000627:therapeutic use; D003300:Copper / Q000652:urine; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006527:Hepatolenticular Degeneration / Q000188:drug therapy* / Q000652:urine; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009048:Motor Skills / Q000187:drug effects; D010396:Penicillamine / Q000627:therapeutic use
D002614:Chelating Agents; D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D003300:Copper; D010396:Penicillamine; D006719:Homovanillic Acid